Chronic postsurgical pain (CPSP) is a common and debilitating complication of major surgery. We undertook a pilot study at three hospitals to assess the feasibility of a proposed large multicentre placebo-controlled randomised trial of intravenous perioperative ketamine to reduce the incidence of CPSP. Ketamine, 0.5 mg/kg pre-incision, 0.25 mg/kg/hour intraoperatively and 0.1 mg/kg/hour for 24 hours, or placebo, was administered to 80 patients, recruited over a 15-month period, undergoing abdominal or thoracic surgery under general anaesthesia. The primary endpoint was CPSP in the area of the surgery reported at six-month telephone follow-up using a structured questionnaire. Fourteen patients (17.5%) reported CPSP (relative risk [95% confidence interval] if received ketamine 1.18 [0.70 to 1.98], P=0.56). Four patients in the treatment group and three in the control group reported ongoing analgesic use to treat CPSP and two patients in each group reported their worst pain in the previous 24 hours at ≥3/10 at six months. There were no significant differences in adverse event rates, quality of recovery scores, or cumulative morphine equivalents consumption in the first 72 hours. Numeric Rating Scale pain scores (median [interquartile range]) for average pain in the previous 24 hours among those patients reporting CPSP were 17.5 [0 to 40] /100 with no difference between treatment groups. A large (n=4,000 to 5,000) adequately powered multicentre trial is feasible using this population and methodology.
A wide variety of agents have been investigated for their potential preventive effect on CPSP, including gabapentinoids, lidocaine, and N-methyl-D-aspartate (NMDA) receptor antagonists 12, 13 . In general, studies have been small and underpowered. A recent systematic review concluded that perioperative intravenous (IV) ketamine was the only agent with promise in preventing CPSP at six months postoperatively, with an odds ratio versus placebo of 0.50 (95% confidence interval [CI] 0.33 to 0.76, P=0.001) across eight heterogeneous small studies (516 patients). The authors cautioned that large trial data were lacking and needed 14 .
Ketamine is a non-selective potent NMDA receptor antagonist that is commonly used in the management of refractory acute postoperative pain 15 . The NMDA receptor in the spinal cord is understood to play a pivotal role in the process of central sensitisation that contributes to development of chronic pain, and associated neuroinflammation [16] [17] [18] . Ketamine has a wide therapeutic index, but analgesic dosage is limited by side-effects such as hallucinations, dysphoria and emergence agitation (in up to 10% of patients), and it has abuse potential.
We undertook a pilot study for a proposed large multicentre placebo-controlled trial of perioperative IV ketamine for 24 hours to reduce the incidence of CPSP in patients undergoing major surgery. The objectives for this pilot study were to provide an estimate of the incidence of the primary endpoint and expected recruitment rate in the chosen study population; assess loss to follow-up rates and protocol compliance, and its acceptability to patients, and clinical and research staff; and allow workload and cost estimation and identify adverse event rates at the drug doses chosen.
Materials and methods
This pilot study was approved by the Human Research Ethics Committee at each site (principal site approval number: HREC/13/Austin/34). The study was registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12614000247673). Therapeutic Goods Administration Clinical Trial Notification Scheme acknowledgement (2015/004625) was obtained for the study, as ketamine is only approved for use as an anaesthetic in Australia. An arbitrary sample size was chosen of 80 adult patients, who were recruited after written informed consent was obtained, across three public hospitals in Victoria, Australia (Austin Hospital, Royal Melbourne Hospital and Ballarat Base Hospital).
Eligible patients were between 18 and 85 years of age undergoing abdominal or thoracic surgery (including video-assisted thoracic surgery), breast surgery, or inguinal herniorrhaphy, involving a combined skin incision length of at least 8 cm, under relaxant general anaesthesia, with a planned length of hospital stay of at least one night. Exclusion criteria included inability to provide informed consent, poor English language comprehension, pregnancy, body mass index over 40 kg/m 2 or weight over 130 kg, American Society of Anesthesiologists physical status 4 or 5, uncontrolled hypertension (systolic blood pressure more than 180 mmHg), heart failure, intracranial surgery, history of haemorrhagic stroke, previous adverse reaction to ketamine, a documented chronic regional pain syndrome, epilepsy or history of convulsions, or a history of psychiatric disorder or drug abuse.
Patients were randomised using pre-prepared sealed envelopes to receive a double-blind IV infusion of ketamine (treatment group) or normal saline (control group). The active drug was prepared by a research staff member such that the attending anaesthetist, operating room and postanaesthesia care unit (PACU) staff, and staff collecting all intraoperative and postoperative data were blinded to treatment allocation.
The treatment protocol was designed to be consistent with the concept of 'preventive' analgesia, requiring commencement of the intervention before surgical incision and continuation during and after surgery [19] [20] [21] . Intraoperative infusion was delivered by syringe driver, as a solution of ketamine (200 mg in 40 ml) or normal saline (40 ml). In the intervention group, a bolus of 0.5 mg/kg was given after induction of anaesthesia and before surgical incision, followed by 0.25 mg/kg/hour intraoperatively until commencement of skin closure, or an equivalent rate of normal saline in the control group.
In the PACU, an infusion of ketamine at 0.1 mg/kg/hour or equivalent rate of normal saline was commenced and continued for 24 hours on the postoperative ward, or until hospital discharge. The method of delivery, and equipment used (infusion pump and drug dilution and volumes) for the postoperative double-blinded infusion were made consistent with local hospital ward protocols.
Relaxant general anaesthesia was induced and maintained with the attending anaesthetist's choice of drugs, except that the use of gabapentin, pregabalin, nitrous oxide, and openlabel ketamine was prohibited. Standard clinical monitoring was used. Normothermia was maintained with forced air warming.
The postoperative analgesia regimen consisted of postoperative opioids delivered as bolus doses or via patient-controlled analgesia. Regional blockade or use of local anaesthetic infiltration was permitted only at the end of surgery. Ancillary analgesia (including non-steroidal antiinflammatories, cyclooxygenase inhibitors and paracetamol) could be administered according to standard practice.
Data collection
Pain and its associated outcomes were assessed in accordance with the core domains outlined in the recommendations of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 22, 23 . Pain and its effect on activities of daily living were measured using the modified Brief Pain Inventory short form which incorporated Numerical Rating Scale (NRS) pain scores out of 100 for average, worst and least pain in the last 24 hours 24 . Pain quality was measured using the Neuropathic Pain Questionnaire (NPQ) 25 . Disability was measured using the World Health Organization Disability Assessment Schedule (WHODAS) 2.0, which has been validated for perioperative outcome research 26 . The Kessler K-10 Psychological Distress Scale (K-10), and the Patient Catastrophising Scale (PCS) were used to measure mood and psychological wellbeing 27, 28 .
Baseline preoperative data collection included demographic data, major comorbidities and preoperative medications, modified Brief Pain Inventory short form, WHODAS and K-10. Intra-and postoperative drugs and doses of all analgesics including all opioids given during surgery and in the first 72 hours or up to discharge from hospital were recorded, as were minimum, maximum and mean NRS pain scores. Time to discharge from PACU and from hospital, and quality of recovery (QoR) were recorded using the QoR-15 scale on the day after surgery 29 . The occurrence of adverse events or sideeffects that could possibly be attributed to ketamine or which caused the study infusion to be discontinued were recorded. Total daily opioid consumption doses were converted to morphine equivalents for subsequent statistical comparisons (morphine 1 mg = fentanyl 10 µg = oxycodone 2 mg = tramadol 10 mg).
Post-discharge follow-up was done via telephone contact at three and six months postoperatively using a structured interview, a model which was extensively tested in follow-up studies in previous large multicentre trials in anaesthesia 4, 5, [30] [31] [32] [33] . At the three-month follow-up, patients were asked if they had experienced pain in the area of the surgery in the preceding month. If so, they were asked about analgesic drugs and doses, and need for medical assistance, and the modified Brief Pain Inventory short form and NPQ were administered. All patients were given a repeat WHODAS and K-10 questionnaire regardless of the presence or absence of pain. This process was repeated at the six-month followup, with the addition of the PCS in patients reporting pain.
We defined our primary endpoint (CPSP) as the presence of pain in the area of the surgery in the preceding month reported by the patient at the six-month follow-up contact on an intention-to-treat basis 4, 5 . Our null hypothesis was that IV ketamine given before and following surgical incision does not reduce the incidence of CPSP in our population sample.
Secondary endpoints included the incidence of CPSP allowing for any loss to follow-up, the effect of IV ketamine on acute and chronic pain severity and character (NRS, modified Brief Pain Inventory, NPQ), QoR-15, quality of life assessment (WHODAS, K-10, PCS), change in WHODAS and K-10 from preoperative baseline, cumulative morphine equivalents consumption over the first 72 hours, cumulative NRS pain scores over the first 72 hours, side-effects and safety data. The relationship of these variables to the presence or absence of CPSP, irrespective of treatment allocation, was also examined. Six-month data were assessed using pairwise deletion to account for missing data due to loss to follow-up. The loss to follow-up rate and level of data completeness were also examined.
Statistical analyses
Binary outcomes, including the primary endpoint, were compared using the chi-squared test. Continuous variables, such as opioid consumption, were compared after normality testing with either the unpaired two-tailed t-test for normally distributed data or the Kruskal-Wallis test for non-normal data. Ordinal or other data such as NRS pain scores or WHODAS and K-10 scores were compared using the Kruskal-Wallis test. The association of preoperative and postoperative WHODAS and K-10 scores with CPSP incidence were tested using univariable ordered logistic regression. Analyses were done using Stata 12.0.
Results
The recruitment target of 80 patients was reached 15 months after the commencement of participant screening at the Austin Hospital in January 2014. Forty-six patients were randomised at the Austin Hospital, and 26 at the Royal Melbourne Hospital. A further eight patients were randomised at the Ballarat Base Hospital, where recruitment commenced at the start of 2015. Across the three recruitment centres, there were no significant differences between treatment groups in baseline characteristics ( Table 1) .
Primary endpoint
On an intention-to-treat basis, 14 
Secondary analyses
At six-month telephone contact, four patients had died (all in the control group) and one patient could not be contacted, despite repeated attempts, leaving 75 patients completing follow-up. Data completeness among the surviving patients exceeded 98%. One patient in the control group who reported no wound pain at three months, but who suffered a wound infection and dehiscence requiring readmission at four months and subsequently reported wound pain at six months, was excluded from the secondary analysis. Allowing for loss to follow-up and exclusions, 13 There were no significant differences at six months between treatment groups in psychological wellbeing on the K-10 (median [IQR] treatment group 12 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Two patients from the treatment group and three from the control group had CPSP with neuropathic characteristics (25% and 50% respectively) according to NPQ scoring criteria 25 . Three of these patients rated their worst pain at 40/100 or greater on the modified Brief Pain Inventory.
Adverse event rates were similar (four in the treatment group, six in the control group). These events included hallucinations, delayed emergence, dizziness, diplopia and confusion ( Table 3) .
Regardless of treatment allocation, CPSP incidence was associated with poorer psychological wellbeing using K-10 score (median [IQR] 16 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] versus 11 [10] [11] [12] [13] [14] [15] [16] (Table 4 ). CPSP was also associated with greater disability at six months on the WHODAS (median [IQR]) 5.5 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] versus 1 [0-7] P=0.029), but not change in WHODAS from preoperatively (median [IQR] 0.5 [-2--3] versus 0 [-1-3], P=0.786). CPSP incidence was associated with a higher preoperative WHODAS (P=0.002) but not preoperative K-10 (P=0.13).
Exclusion of the patient in the control group who reported no wound pain at three months, but who suffered a wound infection and dehiscence requiring readmission at four months and subsequently reported wound pain at 
Discussion
This pilot study of patients undergoing abdominal or thoracic surgery with significant risk of development of CPSP found no effect of perioperative IV ketamine on CPSP incidence at six months. Similarly, there were no significant differences in pain scores, nor in disability or psychological wellbeing between treatment and control groups at six months. Being a pilot study, it was not powered to detect a clinically significant treatment effect on CPSP incidence, despite the higher rate of incidence of CPSP in our population sample than found in previous large studies 4, 5 . Nevertheless this is the second largest placebo-controlled double-blinded comparison conducted to date of IV ketamine measuring CPSP outcomes in a similar surgical population 14 .
We have demonstrated the feasibility of a large randomised controlled trial. Recruitment rates, protocol adherence and acceptability were satisfactory. The loss to follow-up rate (five out of 80, 6.25%) was comparable to that found in the previous large 12-month follow-up study of over 3,000 patients in the ENIGMA-II trial 5 . Four of our patients had died, and only one patient believed to be surviving was not contactable for interview, at six months. Data completeness among the surviving patients was excellent, exceeding 98%. This information needs to be factored into sample size estimations of a future trial based on this protocol.
Compared with previous larger studies, median NRS pain scores for average pain in the previous 24 hours among those patients reporting CPSP were low 4, 5 . Interestingly, there were no significant differences in cumulative opioid consumption nor NRS pain scores between the treatment and control groups in the first 24 or 72 hours. This lack of effect on acute pain severity raises the question of whether our ketamine dose was adequate. Our ketamine dose and duration of administration were in the mid-range of previously published placebo-controlled trials of the effect of IV ketamine on CPSP, and comparable to those used by Remerand et al in their larger positive study in patients undergoing elective total hip arthroplasty [34] [35] [36] . Larger doses are expected to be accompanied by increased rates of side-effects, which might limit the applicability of the treatment routinely to a broad surgical population. Nevertheless, a higher infusion rate should be considered, particularly in the postoperative period, where assessment of side-effects and adjustment of dose rates are practicable and consistent with usual clinical practice. A more prolonged duration of administration, for example up to 72 hours postoperatively to adequately cover the period of maximum acute pain, is another important consideration. However, in the setting of a large pragmatic multicentre trial, a postoperative IV administration protocol would need to reflect the practicalities of modern surgical management with early mobilisation and enhanced recovery after surgery principles across a wide variety of surgery. There was no evidence of a high adverse event rate with ketamine at the dose rates chosen, which is reassuring, and quality of recovery was similar between the two groups. An alternative explanation is that this pilot study was simply underpowered for these secondary endpoints, given the wide range of measurements reported for these variables.
We demonstrated an association between the presence of CPSP and worse disability and depression at six months, irrespective of treatment allocation. While previous studies have suggested that pre-existing disability and psychological distress are predisposing factors for CPSP, this association in our study nevertheless remained significant for depression when change of K-10 score from baseline was considered instead 9, 10 . The effect of chronic pain on quality of life, disability, and their associated economic costs have been the subject of extensive evaluation in several countries [37] [38] [39] [40] . Similar assessment for CPSP is warranted, and underlies the recommendations of the IMMPACT group that studies such as this routinely include measurements and reporting of these correlates of chronic pain, as important patientcentred outcome measures 22, 23 . These results also require confirmation in a large trial.
Our study has a number of limitations, many of which originate from its pilot function. As mentioned, it was not powered for the primary endpoint. Based on reported rates of CPSP in large follow-up studies of around 12%, power analysis estimates that around 4,000 participants are required to demonstrate a 25% reduction in CPSP. Our study piloted follow-up methodology that we intend to use in a large multicentre study, with structured telephone-based interviews using validated questionnaire tools. Detailed face-to-face assessment, which can allow expert clinical examination of pain characteristics such as allodynia and hyperalgesia for example, is not feasible on that scale, and was not piloted. This however might instead be the basis for planned sub-studies within a large future trial.
Much recent work in the field has focused on the variety of mechanisms involved in the development of chronic pain and on the potential effectiveness of multimodal treatment regimens to improve outcomes. This principle may also apply to preventive treatment strategies applicable to CPSP, such as perioperative ketamine. This study piloted investigation of a single intervention, and this may be seen as a further limitation. However, studies of compound treatment regimens are expensive and complex to run, often requiring multifactorial design to try to identify the contributions of the component agents being studied to patient outcome.
Estimation of study power and sample size for a subsequent large multicentre trial must take several factors into account that are difficult to assess solely from a small pilot study. While we excluded major orthopaedic surgery in this pilot because of concerns about pre-existing chronic pain as a confounder in the primary endpoint assessment, inclusion of this surgical subgroup in a large trial may be warranted, and may increase recruitment rates and overall trial power, given that the incidence of CPSP 12 months after orthopaedic surgery, using similar follow-up methodology, was 17% in the ENIGMA-II trial 5, 36 . Inclusion of thoracic surgery and breast surgery are also likely to increase the primary endpoint rate 6 . With these considerations in mind, the most reliable data on endpoint rates and data attrition comes from the ENIGMA-II trial where a 12.2% overall incidence in CPSP among 2,924 patients was found, with a 5% mortality and loss to followup rate of 12.7% among survivors. Given the younger age demographic expected (55 years in this pilot versus 70 years in ENIGMA-II) and higher survival rates, a loss to follow-up in the order of 10% can be reasonably assumed in the proposed large trial. A sample size of 4,884 patients would therefore provide 90% power to demonstrate a clinically important 25% relative reduction in CPSP incidence at 12 months, allowing for P-value spending for an interim analysis at the midpoint of recruitment. From experience of planning, funding and conduct of recent large anaesthesia trials involving both perioperative and longer term patient data collection, such as the Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF) trial 41 , and the Perioperative Administration of Dexamethasone and Infection (PADDI) trial, a multicentre randomised control trial of this size can be estimated to require in excess of A$4 million in funding. IV ketamine has been identified in a recent systematic review as the only drug intervention with promising evidence for effectiveness 14 , based on the current state of the literature in the field. Given the scale of the problem of CPSP, we believe this justifies the cost and effort of a large randomised trial of this agent, which is feasible using the population and methodology piloted here.
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